keyword
MENU ▼
Read by QxMD icon Read
search

Paclitaxel

keyword
https://www.readbyqxmd.com/read/29679668/a-novel-peptide-ligand-rap12-of-lrp1-for-glioma-targeted-drug-delivery
#1
Huitong Ruan, Zhilan Chai, Qing Shen, Xishan Chen, Bingxia Su, Cao Xie, Changyou Zhan, Shengyu Yao, Huan Wang, Mingfei Zhang, Man Ying, Weiyue Lu
The receptor associated protein (RAP) is a 39 kDa chaperone protein, binding tightly to low-density lipoprotein receptor-related protein-1 (LRP1) that is overexpressed in glioma, tumor neovasculature, vasculogenic mimicry (VM), the blood-brain barrier (BBB) and the blood-brain tumor barrier (BBTB). Herein, we miniaturized the RAP protein into a short peptide RAP12 (EAKIEKHNHYQK) aiding by computer-aided peptide design technique. RAP12 contained the essential lysines at the positions 253 and 256. The binding affinity of RAP12 to LRP1 was theoretically and experimentally evaluated...
April 18, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29676924/paclitaxel-loaded-ph-sensitive-liposome-new-insights-on-structural-and-physicochemical-characterization
#2
Liziane Oliveira Fonseca Monteiro, Angelo Malachias, Gwenaelle Pound-Lana, Rogerio Magalhães-Paniago, Vanessa Carla Furtado Mosqueira, Mônica Cristina Oliveira, Andre Branco de Barros, Elaine Amaral Leite
A long-circulating and pH-sensitive liposome containing PTX (SpHL-PTX) was recently developed by our group. Once at an acidic environment, e.g. tumor, these liposomes undergo destabilization releasing the encapsulated drug. In this way, the aim of this study was evaluate the molecular and supramolecular interactions between the lipid bilayer and PTX in similar biological environment conditions. High sensitivity analyses of SpHL-PTX structures were obtained by small angle X-ray scattering (SAXS) technique combined with other techniques such as DLS, AF4, TEM and HPLC...
April 20, 2018: Langmuir: the ACS Journal of Surfaces and Colloids
https://www.readbyqxmd.com/read/29675791/chemotherapy-treatment-is-associated-with-altered-pd-l1-expression-in-lung-cancer-patients
#3
Lívia Rojkó, Lilla Reiniger, Vanda Téglási, Katalin Fábián, Orsolya Pipek, Attila Vágvölgyi, László Agócs, János Fillinger, Zita Kajdácsi, József Tímár, Balázs Döme, Zoltán Szállási, Judit Moldvay
OBJECTIVES: While the predictive value of programmed cell death ligand-1 (PD-L1) protein expression for immune checkpoint inhibitor therapy of lung cancer has been extensively studied, the impact of standard platinum-based chemotherapy on PD-L1 or programmed cell death-1 (PD-1) expression is unknown. The aim of this study was to determine the changes in PD-L1 expression of tumor cells (TC) and immune cells (IC), in PD-1 expression of IC, and in the amount of stromal mononuclear cell infiltration after platinum-based chemotherapy in patients with lung cancer...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29674766/the-combination-of-gemcitabine-cisplatin-and-paclitaxel-as-salvage-chemotherapy-for-advanced-urothelial-carcinoma
#4
Takeshi Hirata, Masanori Hanamoto, Kazuma Ogura, Nobuki Hayashi, Kosuke Takamura, Kohei Edamura, Shin Ebara, Takashi Saika
There is no standard second-line or salvage treatment for advanced urothelial carcinoma (UC). Here we investigated the efficacy and safety of gemcitabine, cisplatin, and paclitaxel (GCP) combination chemotherapy as salvage chemotherapy for advanced UC. We retrospectively analyzed the cases of 23 patients with advanced UC who showed progression or recurrence after cisplatin-based chemotherapy. Gemcitabine (1000 mg/m2), and paclitaxel (80 mg/m2) were administered on days 1 and 8. Cisplatin (70 mg/m2) was administered on day 1...
April 2018: Acta Medica Okayama
https://www.readbyqxmd.com/read/29674442/first-report-of-dramatic-tumor-responses-with-ramucirumab-and-paclitaxel-after-progression-on-pembrolizumab-in-two-cases-of-metastatic-gastroesophageal-adenocarcinoma
#5
Sakti Chakrabarti, Haidong Dong, Harshita R Paripati, Helen J Ross, Harry H Yoon
Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma...
April 19, 2018: Oncologist
https://www.readbyqxmd.com/read/29674231/photoinduced-peg-deshielding-from-ros-sensitive-linkage-bridged-block-copolymer-based-nanocarriers-for-on-demand-drug-delivery
#6
Jie Li, Chunyang Sun, Wei Tao, Ziyang Cao, Haisheng Qian, Xianzhu Yang, Jun Wang
Controlling poly(ethylene glycol) (PEG) shielding/deshielding at the desired site of action exhibits great advantages for nanocarrier-based on-demand drug delivery in vivo. However, the current PEG deshielding strategies were mainly designed for anticancer drug delivery; even so, their applications are also limited by tumor heterogeneity. As a proof-of-concept, we explored a photoinduced PEG deshielding nanocarrier TK-NPCe6&PTX to circumvent the aforementioned challenge. The TK-NPCe6&PTX encapsulating chlorin e6 (Ce6) and paclitaxel (PTX) was self-assembled from an innovative thioketal (TK) linkage-bridged diblock copolymer of PEG with poly(d,l-lactic acid) (PEG-TK-PLA)...
April 10, 2018: Biomaterials
https://www.readbyqxmd.com/read/29673198/chemoresistance-to-cancer-treatment-benzo-%C3%AE-pyrene-as-friend-or-foe
#7
Kevin Dzobo, Naseeha Hassen, Dimakatso Alice Senthebane, Nicholas Ekow Thomford, Arielle Rowe, Hendrina Shipanga, Ambroise Wonkam, M Iqbal Parker, Shaheen Mowla, Collet Dandara
Background: Environmental pollution such as exposure to pro-carcinogens including benzo-α-pyrene is becoming a major problem globally. Moreover, the effects of benzo-α-pyrene (BaP) on drug pharmacokinetics, pharmacodynamics, and drug resistance warrant further investigation, especially in cancer outpatient chemotherapy where exposure to environmental pollutants might occur. Method: We report here on the effects of benzo-α-pyrene on esophageal cancer cells in vitro, alone, or in combination with chemotherapeutic drugs cisplatin, 5-flurouracil, or paclitaxel...
April 17, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29671386/k237-modified-thermosensitive-liposome-enhanced-the-delivery-efficiency-and-cytotoxicity-of-paclitaxel-in-vitro
#8
Xudong Fu, Yuanyuan Lu, Jiaping Guo, Hui Liu, Aiping Deng, Changchun Kuang, Xiangyang Xie
This study aimed to develop novel temperature-sensitive liposomes loading paclitaxel (PTX-TSL) and evaluate them in vitro to improve the delivery efficiency and targeting of PTX. K237 peptide was conjugated to the terminal NHS of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[hydroxyl succinimidyl (polyethylene glycol)-(DSPE-PEG-NHS), and K237-modified PTX-TSL (K237-PTX-TSL) was prepared using a film dispersion method. K237-TSL encapsulation with calcein was synthesized and used to determine the cellular uptake of TSL...
April 19, 2018: Journal of Liposome Research
https://www.readbyqxmd.com/read/29671170/physiologically-based-modeling-and-interspecies-prediction-of-paclitaxel-pharmacokinetics
#9
Xiaowei Zang, Leonid Kagan
The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol® ) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported paclitaxel plasma and tissue concentration-time data following single intravenous bolus administration of Taxol® to mice were used; and the PBPK model included plasma, liver, lungs, kidneys, spleen, heart, gastrointestinal tract, and remainder compartments...
April 18, 2018: Journal of Pharmacokinetics and Pharmacodynamics
https://www.readbyqxmd.com/read/29670925/pseudocirrhosis-in-a-patient-with-new-onset-dysphagia-and-history-of-ovarian-carcinoma
#10
Andrew Zanazanian, Amir Kalani, James H Tabibian
Pseudocirrhosis is an infrequently reported clinico-radiologic complication that primarily occurs in a subset of patients with a history of breast carcinoma metastatic to the liver that has been treated with systemic chemotherapy, particularly capecitabine, gemcitabine, trastuzumab, and/or paclitaxel. Even less common are cases of pseudocirrhosis secondary to other (i.e., non-breast) carcinomas. We describe a 43-year-old woman with a history of metastatic ovarian carcinoma treated several years prior with systemic chemotherapy who presented with progressive dysphagia and was found to have gastroesophageal junction adenocarcinoma and, incidentally, pseudocirrhosis...
2018: ACG Case Reports Journal
https://www.readbyqxmd.com/read/29670842/investigation-of-effective-parameters-on-size-of-paclitaxel-loaded-plga-nanoparticles
#11
Fatemeh Madani, Seyedeh Sara Esnaashari, Basil Mujokoro, Farid Dorkoosh, Masood Khosravani, Mahdi Adabi
Purpose: The size of polymeric nanoparticles is considered as an effective factor in cancer therapy due to enterance into tumor tissue via the EPR effect. The purpose of this work was to investigate the effective parameters on poly(lactic-co-glycolic acid)-paclitaxel (PLGA -PTX) nanoparticles size. Methods: We prepared PLGA-PTX nanoparticles via single emulsion and precipitation methods with variable paremeters including drug concentration, aqueous to organic phase volume ratio, polymer concentration, sonication time and PVA concentration...
March 2018: Advanced Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/29669928/cx3cr1-identifies-pd-1-therapy-responsive-cd8-t-cells-that-withstand-chemotherapy-during-cancer-chemoimmunotherapy
#12
Yiyi Yan, Siyu Cao, Xin Liu, Susan M Harrington, Wendy E Bindeman, Alex A Adjei, Jin Sung Jang, Jin Jen, Ying Li, Pritha Chanana, Aaron S Mansfield, Sean S Park, Svetomir N Markovic, Roxana S Dronca, Haidong Dong
Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti-PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for the successful chemoimmunotherapy is not completely understood. Here we show that a subset of circulating CD8+ T cells expressing the chemokine receptor CX3CR1 are able to withstand the toxicity of chemotherapy and are increased in patients with metastatic melanoma who responded to chemoimmunotherapy (paclitaxel and carboplatin plus PD-1 blockade)...
April 19, 2018: JCI Insight
https://www.readbyqxmd.com/read/29668492/paclitaxel-induced-organizing-pneumonia-with-intractable-hemoptysis
#13
Arjun Saradna, Bhavyaa Bahl, Parita Soni, Paurush Ambesh, William Pascal, Stephan Kamholz
No abstract text is available yet for this article.
April 9, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29668470/secondary-hodgkin-lymphoma-and-myelodysplastic-syndrome-mds-after-paclitaxel-carboplatin-treatment-in-a-patient-with-small-cell-lung-cancer
#14
Marija Petrusevska, Irina Panovska Stavridis, Kristina Mladenovska, Gordana Petrushevska
Herein synchronous occurrence of Hodgkin lymphoma and secondary myelodysplastic syndrome in a 60 year old male patient with small cell lung cancer treated with combined chemotherapy (carboplatin and paclitaxel) and radiotherapy is presented. The objective of this report is to stress the importance of documenting and monitoring adverse drug reactions that arise from chemotherapy. After four years of treatment with the combined chemotherapy, the patient presented inguinal lymphadenopathy and enlarged lymph nodes and histopathology rapport was suggestive for plasmacytoid variant of Castleman disease...
December 1, 2017: Prilozi (Makedonska Akademija Na Naukite i Umetnostite. Oddelenie za Medicinski Nauki)
https://www.readbyqxmd.com/read/29666962/activity-of-indatuximab-ravtansine-against-triple-negative-breast-cancer-in-preclinical-tumor-models
#15
Kurt Schönfeld, Peter Herbener, Chantal Zuber, Thomas Häder, Katrin Bernöster, Christoph Uherek, Jörg Schüttrumpf
PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062) is an antibody-drug-conjugate that specifically targets CD138-expressing cells and has previously shown clinical activity in multiple myeloma. Here we show indatuximab ravtansine as a potential mono- and combination therapy for TNBC. METHODS: The effects of indatuximab ravtansine were assessed in vitro in SK-BR-3 and T47D breast cancer cell lines...
April 17, 2018: Pharmaceutical Research
https://www.readbyqxmd.com/read/29666801/current-therapeutic-landscape-for-advanced-gastroesophageal-cancers
#16
REVIEW
Anthony Lopez, Kazuto Harada, Dilsa Mizrak Kaya, Jaffer A Ajani
Treatment of advanced gastroesophageal cancers remains challenging for clinicians, patients, and caregivers alike. Despite considerable research, the therapeutic armamentarium is restricted and hardly personalized. In the first-line setting, trastuzumab with a fluoropyrimidine and platinum agent is the standard-of-care in patients with HER2-positive tumor. For the others, a platinum-based doublet (preferably with oxaliplatin) is recommended. Three-drug cytotoxic regimens should be reserved for exceptional cases where patients have good performance status...
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29665849/an-innovative-immunotherapeutic-strategy-for-ovarian-cancer-clec10a-and-glycomimetic-peptides
#17
Laura L Eggink, Katherine F Roby, Robert Cote, J Kenneth Hoober
BACKGROUND: Receptors specific for the sugar N-acetylgalactosamine (GalNAc) include the human type II, C-type lectin receptor macrophage galactose-type lectin/C-type lectin receptor family member 10A (MGL/CLEC10A/CD301) that is expressed prominently by human peripheral immature dendritic cells, dendritic cells in the skin, alternatively-activated (M2a) macrophages, and to lesser extents by several other types of tissues. CLEC10A is an endocytic receptor on antigen-presenting cells and has been proposed to play an important role in maturation of dendritic cells and initiation of an immune response...
April 17, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29663921/multifunctional-hyaluronic-acid-decorated-redox-responsive-magnetic-complex-micelle-for-targeted-drug-delivery-with-enhanced-antitumor-efficiency-and-anti-cell-migration-activity
#18
Mangmang Sang, Zhongtao Zhang, Fulei Liu, Lejian Hu, Lingchao Li, Li Chen, Feng Feng, Wenyuan Liu, Wei Qu
A novel multifunctional hyaluronic acid-decorated redox-responsive magnetic complex micelle (HA/CSO-SS-Hex/Fe3O4/PTX) based on a reducible hexadecanol-modified chitosan oligosaccharide polymer micelle (CSO-SS-Hex) coated with hyaluronic acid (HA) and loaded with paclitaxel (PTX) Fe3O4 nanoparticles is developed. HA is coated onto the surface of micelles via electrostatic absorption and acts as a targeting ligand for CD44 over expression in many tumor cells. A CSO-SS-Hex polymer micelle was used for PTX incorporation and GSH-triggered intracellular release...
March 1, 2018: Journal of Biomedical Nanotechnology
https://www.readbyqxmd.com/read/29663729/hepatitis-b-infection-reported-with-cancer-chemotherapy-analyzing-the-us-fda-adverse-event-reporting-system
#19
Akimasa Sanagawa, Yuji Hotta, Tomoya Kataoka, Yasuhiro Maeda, Masahiro Kondo, Yoshihiro Kawade, Yoshihiro Ogawa, Ryohei Nishikawa, Masahiro Tohkin, Kazunori Kimura
We conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database on spontaneously reported adverse events to evaluate the association between anticancer drug therapy and hepatitis B infection. Reports of hepatitis B infection were retrieved from the FAERS database. The reporting odds ratio (ROR) was used to estimate the association between hepatitis B infection and various anticancer agents and drug combinations. We detected statistically significant risk signals of hepatitis B for 33 of 64 anticancer agents by ROR (26 cytotoxicity drugs and seven molecular-targeted drugs)...
April 16, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29662002/carotenoid-lutein-selectively-inhibits-breast-cancer-cell-growth-and-potentiates-the-effect-of-chemotherapeutic-agents-through-ros-mediated-mechanisms
#20
Xiaoming Gong, Joshua R Smith, Haley M Swanson, Lewis P Rubin
Increasing evidence suggests that dietary carotenoids may reduce the risk of breast cancer. However, anti-breast cancer effects of carotenoids have been controversial, albeit understudied. Here, we investigated the effects of specific carotenoids on a wide range of breast cancer cell lines, and found that among several carotenoids (including β-carotene, lutein, and astaxanthin), lutein significantly inhibits breast cancer cell growth by inducing cell-cycle arrest and caspase-independent cell death, but it has little effect on the growth of primary mammary epithelial cells (PmECs)...
April 14, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
35091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"